secwatch.observer — SEC 8-K summary
======================================

Issuer:     CareDx, Inc. (CDNA)
CIK:        0001217234
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001104659-26-050317
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.02, 9.01, 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CareDx acquires Naveris for $160M; Q1 revenue $118M (+39% YoY), raises 2026 guidance
--------------------------------------------------------------------------------

- Upfront cash $160M for Naveris, plus up to $100M in revenue milestones; expands into viral-mediated cancer MRD surveillance.
- Q1 revenue $118M (+39% YoY); Testing Services revenue $91M (+48% YoY); GAAP net income $3M vs loss $10M prior year.
- FY2026 revenue guidance raised to $447M-$465M from $420M-$444M; AEBITDA guidance raised to $43M-$57M.
- Board authorized up to $100M stock repurchase program over 24 months.
- Deal expected to close Q3 2026; neutral to FY2026 AEBITDA; Naveris $34M revenue in 2025 with 65% gross margins.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1217234/000110465926050317/0001104659-26-050317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1217234/000110465926050317/tm2611749d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-050317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer